TCRT
Alaunos Therapeutics, Inc.
Healthcare — Biotechnology
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
None
$0.90
+$0.01 (+1.61%)
Price History
52-Week Range
Sign in to add TCRT to a watchlist or set price alerts.
Fundamentals
| Market Cap | $5.28M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.60 |
| EPS (TTM) | $-2.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -350.30% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 59.0 |
| Beta | -1.06 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.20 |
| 52-Week Low | $1.67 |
| 50-Day Avg | $2.46 |
| 200-Day Avg | $2.90 |
| Avg Volume | 16.0K |
| Volume | 139 |
Performance Analysis
NEUTRALTCRT presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($1.67), which could present a value opportunity.
+
RSI at 59.0 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:33 UTC
Back to Screener Export Report